title: Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".
authors.affiliation: Radboud University Medical Centre, Department of Pharmacy, Nijmegen, The Netherlands.
authors.forename: Rob
authors.initials: R
authors.lastname: Aarnoutse
authors.forename: Carolien
authors.initials: C
authors.lastname: Ruesen
authors.forename: Erlina
authors.initials: E
authors.lastname: Burhan
authors.forename: Reinout
authors.initials: R
authors.lastname: van Crevel
authors.forename: Rovina
authors.initials: R
authors.lastname: Ruslami
mesh_terms: D000995:Antitubercular Agents / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000493:pharmacokinetics*; D008297:Male; D011718:Pyrazinamide / Q000493:pharmacokinetics*; D012293:Rifampin / Q000493:pharmacokinetics*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin